A significant peptide update in 2026 has set in motion a significant regulatory shift for some of the most widely researched compounds in the peptide space. 

Following an announcement by Robert F. Kennedy Jr., United States Secretary of Health and Human Services, 12 peptides previously classified under FDA Category 2 will be removed from that designation and referred to the Pharmacy Compounding Advisory Committee (PCAC) for independent scientific evaluation.

For practitioners, researchers, and those who have been navigating the restrictions created by the 2023 Category 2 designations, this development represents a meaningful step toward regulatory clarity. 

The PCAC review process, beginning at meetings scheduled for July 2026, will assess each peptide on its scientific merits using the full body of clinical, pharmacological, and safety evidence available.

Understanding FDA Category 2: What It Was and Why It Matters

The FDA’s bulk drug substance nomination process governs which compounds compounding pharmacies may legally use when preparing medications for individual patients under Section 503A of the Federal Food, Drug, and Cosmetic Act. 

Compounds reviewed under this process are assigned to categories based on their evidence profile and safety assessment.

Category 2 was reserved for bulk drug substances considered to raise significant safety risks. Placement in this category effectively barred compounding pharmacies from using these substances in patient preparations, removing them from the regulated compounding pathway entirely.

In September 2023, the Biden-era FDA assigned a range of well-researched peptides to Category 2. 

Secretary Kennedy’s announcement in 2026 acknowledged directly that this decision had unintended and harmful consequences, describing it as having pushed demand toward an unregulated black market rather than reducing access to potentially beneficial compounds. 

The 2026 peptide update initiates the process of correcting this through independent scientific review.

The 12 Peptides Affected by the 2026 FDA Update

The following 12 peptides will be removed from Category 2 and brought before the PCAC for evaluation:

1. BPC-157: A widely studied cytoprotective peptide with an extensive preclinical research profile spanning tissue repair, gastrointestinal protection, and anti-inflammatory activity across multiple organ systems.
2. Thymosin Beta-4 Fragment (LKKTETQ): A fragment of Thymosin Beta-4 studied for its roles in tissue repair, wound healing, and immune modulation.
3. Epitalon: A pineal gland bioregulator peptide with several decades of research documenting its capacity to stimulate telomerase activity and support cellular longevity.
4. GHK-Cu: A copper peptide researched for its roles in collagen synthesis, wound healing, and anti-inflammatory activity.
5. MOTS-C: A mitochondrial-derived peptide studied for its effects on metabolic regulation, cellular energy balance, and insulin sensitivity.
6. DSIP (Emideltide): Delta Sleep-Inducing Peptide, researched for its influence on sleep architecture and stress response modulation.
7. Dihexa Acetate: A nootropic peptide researched for its effects on cognitive performance, memory consolidation, and neuroplasticity.
8. Ibutamoren Mesylate (MK-677): A growth hormone secretagogue researched for its effects on growth hormone and IGF-1 levels, body composition, and recovery.
9. Melanotan II: A melanocortin receptor agonist researched for its effects on pigmentation, appetite regulation, and libido.
10. KPV: A tripeptide fragment of alpha-MSH studied for its anti-inflammatory and gut-protective properties.
11. Semax (heptapeptide): An ACTH analogue with a well-established research and prescription history in Russia, studied for its nootropic, neuroprotective, and BDNF-upregulating properties.
12. Cathelicidin LL-37: An antimicrobial peptide researched for its role in innate immune defence, wound healing, and antimicrobial activity.

What Is the PCAC and How Does the Review Process Work?

The Pharmacy Compounding Advisory Committee (PCAC) is an independent advisory body that provides recommendations to the FDA on matters related to pharmaceutical compounding. 

Its primary function in this context is to evaluate substances nominated for inclusion on the Section 503A Bulk Drug Substances List, which governs what compounding pharmacies may legally prepare for individual patients.

The next PCAC meetings are scheduled for 23 and 24 July 2026 at the FDA White Oak Campus in Silver Spring, Maryland. 

These meetings will be open to the public both in person and via online teleconferencing. 

A public docket (Docket No. FDA-2025-N-6895) has been established for comments related to the review.

At these meetings, independent experts will evaluate each of the 12 peptides using clinical, pharmacological, and safety evidence. 

The PCAC’s role is advisory. 

The FDA retains the final regulatory decision-making authority.

A positive PCAC recommendation significantly strengthens the case for a substance being added to the 503A Bulk Drug Substances List, which would restore the ability of regulated compounding pharmacies to prepare that compound for patients.

The Evidence Behind the 12 Peptides: Why the Research Matters Now

The strength of the PCAC review process lies in its reliance on scientific evidence. 

For compounds with robust research profiles, the July 2026 meetings represent an opportunity for that evidence to be formally evaluated in the appropriate regulatory forum. 

Several of the 12 peptides in this 2026 peptide update have particularly well-documented research bases.

1. BPC-157: A Prolific Preclinical Research Profile

Few peptides in the research literature match BPC-157 for the volume and consistency of preclinical evidence. 

Over 100 peer-reviewed publications, the majority from Professor Predrag Sikiric’s research group at the University of Zagreb, have documented BPC-157’s cytoprotective, anti-inflammatory, and regenerative properties across the gastrointestinal tract, musculoskeletal system, nervous system, and cardiovascular tissue.

A comprehensive review by Sikiric et al. (2020), published in Gut and Liver, outlined BPC-157’s role as a cytoprotective mediator and its broad organ-protective effects. 

The consistency of findings across multiple tissue types and experimental models makes BPC-157 one of the most evidence-rich compounds entering the PCAC review process.

2. Epitalon: Telomerase Science and Longevity Research

Epitalon‘s research profile spans several decades and is rooted in the work of Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. 

A key study published in the Bulletin of Experimental Biology and Medicine (Khavinson et al., 2003) confirmed that Epitalon induces telomerase activity and promotes telomere elongation in human somatic cells, establishing a mechanistic basis for its classification as a longevity-focused bioregulator peptide.

Beyond telomere biology, Epitalon‘s research profile includes effects on sleep regulation, immune function, and metabolic balance, giving it one of the broadest evidence bases among the 12 peptides in this update.

3. Semax: From Russian Prescription Drug to PCAC Review

Semax occupies a distinctive position among the 12 peptides in this 2026 peptide update. 

As a prescription medication approved in Russia since the late 1990s for the treatment of stroke, cognitive disorders, and neuroprotection, Semax brings a body of real-world clinical use data that most research peptides lack.

Its mechanism of action is well characterised. 

Research by Dolotov et al. (2006), confirmed that Semax upregulates BDNF protein levels and trkB receptor expression in the rat hippocampus following intranasal application, providing a clear neurobiological basis for its nootropic and neuroprotective properties.

Reading the 2026 Peptide Update Accurately

Optimism about this peptide update is warranted. 

The acknowledgement that the 2023 Category 2 decisions created unintended harm, combined with a commitment to follow the science through independent review, represents a genuinely positive shift in regulatory approach. 

At the same time, accuracy about what this update does and does not mean matters.

• Removal from Category 2 is not the same as approval. Each peptide must still pass through the PCAC review process. The committee’s recommendations are advisory, and the FDA makes the final determination. The July 2026 meetings begin that process, they do not conclude it.
• The process is evidence-driven. The PCAC evaluates substances on their scientific merits. Peptides with stronger, more consistent research profiles are better positioned in this process. The volume and quality of published evidence will be central to the committee’s assessment.
• Outcomes will differ between compounds. The 12 peptides in this update have varying research profiles and evidence bases. The PCAC review may produce different outcomes for different compounds. Following the process as it unfolds, rather than assuming uniform results, is the most informed approach.
• The direction of travel is clear. The regulatory intent behind this update, restoring science-based evaluation and shifting demand away from unregulated sources, is a meaningful and welcome development for the entire peptide research community.

Curious About How These Peptides Could Work for You?

The 2026 peptide update brings renewed attention to some of the most researched compounds in the field. 

Whether you are new to Peptide Therapy or looking to refine an existing protocol, understanding which peptides are most relevant to your specific goals requires expert input, not just regulatory news.

Schedule your 1:1 consultation today

Frequently Asked Questions (FAQ’s)

What triggered the 2026 FDA peptide update?

Following the withdrawal of nominations by the original nominators of the 12 affected peptides, Secretary Kennedy announced that the FDA would remove these compounds from Category 2 and refer them to the PCAC for independent scientific evaluation. The announcement explicitly acknowledged that the original 2023 Category 2 designations had driven demand toward unregulated black market sources, creating the risk the classification was intended to prevent.

What happens at the PCAC meeting in July 2026?

Independent experts will evaluate each of the 12 peptides using full clinical, pharmacological, and safety evidence. The meetings are scheduled for 23 and 24 July 2026 at the FDA White Oak Campus and will be accessible online. The PCAC will make recommendations to the FDA, which retains final decision-making authority on regulatory outcomes.

Does this update mean these peptides are now approved?

No. Removal from Category 2 initiates the PCAC review process but does not constitute regulatory approval or unrestricted access. Each peptide will be evaluated independently, and the outcomes of those evaluations will determine the regulatory path forward for each compound.

Which peptides in the update does DN Lab Research carry?

DN Lab Research carries most of these peptides including: BPC-157, Epitalon, Semax, GHK-Cu, MOTS-C, KPV, DSIP, Dihexa Acetate, Melanotan II, Thymosin Beta-4 Fragment, and Cathelicidin LL-37. They are available through the DN Lab Research catalogue. All peptides remain third-party tested, available for fast and reliable delivery with documentation such as certificate of analysis, available upon request.

How can I follow the PCAC review process?

The FDA has established a public docket (Docket No. FDA-2025-N-6895) for comments related to the upcoming PCAC meetings. Updates will be published through official FDA channels. The July 2026 meetings will be open to the public both in person and via online teleconferencing.

Does this update affect peptide access outside the United States?

This 2026 peptide update is specific to the US regulatory framework for pharmaceutical compounding. Researchers and practitioners in other jurisdictions should refer to their own applicable regulations. That said, FDA decisions frequently influence international regulatory conversations, and the outcomes of the PCAC review may have broader implications for the global evidence base surrounding these compounds.

What does this mean for people currently using these peptides?

For current users, this peptide update signals a positive shift toward regulated access rather than any immediate change in availability. The PCAC review process will unfold over the coming months, and its outcomes will determine what regulated compounding access looks like for each compound. Staying informed and working with a qualified specialist to guide protocol decisions remains the most prudent approach.

Written by Elizabeth Sogeke, BSc Genetics, MPH

Elizabeth is a science and medical writer with a background in Genetics and Public Health. She holds a BSc in Genetics and a Master’s in Public Health (MPH), with a focus on mitochondrial science, metabolic health, and healthy aging. Over the past several years, she has worked with leading peptide research laboratories and functional medicine clinics, creating trusted, clinically-informed content that bridges the latest developments in peptide and longevity research with real-world applications.